202 completed. 202 Phase 1, 41 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 202 | Completed 202 |
| Phase 2 | 41 | Completed 41 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiple Ascending Dose Phase 1 Study of ALA-3000 ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR - Treatment Resistant Depression | Phase 1 | Completed | Alar Pharmaceuticals Inc. | 37 | 2025-04-21 | 2025-12-31 |
| ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) ENX-104, Placebo - Major Depressive Disorder | Phase 1 | Completed | Engrail Therapeutics INC | 48 | 2025-02-17 | 2025-12-31 |
| A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode SEP-380135, Placebo - Schizophrenia, Major Depressive Disorder (MDD) | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 43 | 2024-11-07 | 2026-04-24 |
| A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression SP-624, Placebo - Major Depressive Disorder, Depression | Phase 1 | Completed | Sirtsei Pharmaceuticals, Inc. | 26 | 2024-08-22 | 2026-05-28 |
| A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET LV232 40mg, Escitalopram 20 mg, LV232 60mg - Major Depressive Disorder | Phase 1 | Completed | Vigonvita Life Sciences | 20 | 2024-05-30 | 2025-06-10 |
| KET-RO Plus RO DBT for Treatment Resistant Depression Ketamine Infusion plus RO DBT - Treatment Resistant Depression | Phase 1 | Completed | Washington University School of Medicine | 16 | 2023-10-04 | 2026-03-30 |
| Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1) Ketamine (Ketalar) Dose Level 1, Ketamine (Ketalar) Dose Level 2, Ketamine (Ketalar) Dose Level 3 - Pain, Postoperative, Depression, Postpartum | Phase 1 | Completed | Grace Lim, MD, MS | 12 | 2023-09-25 | 2025-09-12 |
| A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules MI078, Placebo - Postpartum Depression | Phase 1 | Completed | Nanjing Minova Pharmaceutical Co., Ltd. | 98 | 2023-09-09 | 2025-05-21 |
| Psilocybin-assisted CBT for Depression Psilocybin, Cognitive behavioral therapy - Major Depressive Disorder | Phase 1 | Completed | University of California, Los Angeles | 16 | 2023-06-27 | 2026-05-19 |
| A Study of BRII-297 in Healthy Adult Subjects BRII-297, Placebo - Postpartum Depression | Phase 1 | Completed | Brii Biosciences Limited | 41 | 2023-05-15 | 2024-01-18 |
| Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD) Zuranolone - Major Depressive Disorder | Phase 1 | Completed | Biogen | 19 | 2023-04-19 | 2025-03-26 |
| Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Toludivenlafaxine hydrochloride sustained-release tablets - Major Depressive Disorder | Phase 1 | Completed | Shanghai Mental Health Center | 6 | 2023-03-02 | 2023-07-27 |
| An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain MIJ821 - Major Depressive Disorder | Phase 1 | Completed | Novartis Pharmaceuticals | 10 | 2023-01-11 | 2024-04-01 |
| IM and IV SPL026 Drug Product in Healthy Participants SPL026 IV, SPL026 IM - Major Depressive Disorder | Phase 1 | Completed | Small Pharma Ltd | 14 | 2023-01-03 | 2024-03-22 |
| SPL026 With or Without SSRIs in Participants With MDD SPL026 - Major Depressive Disorder | Phase 1 | Completed | Small Pharma Ltd | 18 | 2022-12-13 | 2024-06-14 |
| Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers apimostinel, Placebo - Major Depressive Disorder | Phase 1 | Completed | Syndeio Biosciences, Inc | 40 | 2022-10-15 | 2023-04-11 |
| D-Cycloserine+iTBS PK Study D-cycloserine, Transcranial Magnetic Stimulator - Major Depressive Disorder | Phase 1 | Completed | University of Calgary | 12 | 2022-10-12 | 2023-09-11 |
| Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg - Major Depressive Disorder (MDD | Phase 1 | Completed | Seasons Biotechnology (Taizhou) Co., Ltd. | 30 | 2022-09-19 | 2023-04-13 |
| Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Vortioxetine Hemihydrobromide Orally Disintegrating Tablets - Major Depressive Disorder (MDD) | Phase 1 | Completed | Seasons Biotechnology (Taizhou) Co., Ltd. | 24 | 2022-09-18 | 2023-04-13 |
| A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder CYB003, Psychotherapy, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | Cybin IRL Limited | 57 | 2022-08-02 | 2024-03-25 |
Showing 20 of 202. Sign in to see all of them.
Depressive Disorder, Major (145) · Depression (52) · Anxiety Disorders (15) · Depressive Disorder, Treatment-Resistant (15) · Mood Disorders (10) · Bipolar Disorder (9) · Stress Disorders, Post-Traumatic (9) · Depression, Postpartum (6) · Dysthymic Disorder (6) · Mental Disorders (5) · Schizophrenia (4) · Generalized Anxiety Disorder (3) · Panic Disorder (3) · Phobia, Social (3)
Mental Disorders (197) · Mood Disorders (192) · Behavior (53) · Behavioral Symptoms (50) · Trauma and Stressor Related Disorders (11) · Bipolar and Related Disorders (9) · Stress Disorders, Traumatic (7) · Female Urogenital Diseases and Pregnancy Complications (6) · Pathological Conditions, Signs and Symptoms (6) · Pregnancy Complications (6) · Puerperal Disorders (6) · Urogenital Diseases (6) · Schizophrenia Spectrum and Other Psychotic Disorders (5) · Chemically-Induced Disorders (4)
alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol (16) · Ketamine (11) · Desvenlafaxine Succinate (6) · Escitalopram (6) · Cognitive Behavioral Therapy (5) · Sertraline (5) · Citalopram (4) · Paroxetine (4) · Therapeutics (4) · seltorexant (4) · 1-(3-(2-(4-(2-methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone (3) · Amisulpride (3) · Duloxetine Hydrochloride (3) · Fluoxetine (3) · Lithium (3)
GlaxoSmithKline (27) · Eli Lilly and Company (17) · Luye Pharma Group Ltd. (7) · Janssen Research & Development, LLC (6) · National Institute of Mental Health (NIMH) (5) · University of California, Los Angeles (5) · Mclean Hospital (4) · Butler Hospital (3) · New York State Psychiatric Institute (3) · Seasons Biotechnology (Taizhou) Co., Ltd. (3) · Small Pharma Ltd (3) · Syndeio Biosciences, Inc (3) · Washington University School of Medicine (3) · Astellas Pharma Inc (2) · Boehringer Ingelheim (2)
United States (106) · United Kingdom (20) · China (16) · Germany (15) · Canada (8) · Netherlands (8) · Australia (7) · Belgium (4) · Brazil (4) · Japan (4) · India (3) · Israel (2) · Argentina (1) · Bulgaria (1) · Denmark (1)
Amy Sun, MD, PhD, MBA (2) · Catherine Harmer (2) · Diego A Pizzagalli, PhD (2) · Fabian Devlin, MD (2) · Ronald M Burch, MD PhD (2) · Sherwood Brown, MD, PhD (2) · Tim Dalgleish, PhD (2) · Aaron Koenig, MD (1) · Abhishek Datta, PhD (1)
PMID 31784354, PMID 32241310, PMID 35963959, PMID 16319710, PMID 16585452, PMID 16894061, PMID 17429407, PMID 18061147, PMID 18996507, PMID 19545857, PMID 19744406, PMID 19897179, PMID 19914605, PMID 19995444, PMID 20673547, PMID 20679587, PMID 21450159, PMID 21459988, PMID 21731830, PMID 21736514, PMID 22065593, PMID 22125120, PMID 22296967, PMID 22297150, PMID 22409700, PMID 22473055, PMID 22521148, PMID 22570264, PMID 22722512, PMID 22945620, PMID 23300127, PMID 23482332, PMID 23562618, PMID 23685546, PMID 23805231, PMID 23916389, PMID 23990896, PMID 24191345, PMID 24462229, PMID 24643964, PMID 25169854, PMID 25271445, PMID 25295436, PMID 25400146, PMID 25451430, PMID 25592045, PMID 26187603, PMID 26228403, PMID 26531124, PMID 27233466
2016 (3), 2017 (2), 2014 (1), 2015 (1), 2018 (1), 2019 (1), K01DA029645 (1), K23MH064528 (1), K23MH074860 (1), K24MH102743 (1), P20MH090318 (1), R01AA024933 (1), R01MH068376 (1), R01MH074807 (1), R01MH084931 (1)